Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

Deferoxamine-induced dysplasia-like skeletal abnormalities at radiography and MRI.

Seif El Dien HM, Esmail RI, Magdy RE, Lotfy HM.

Pediatr Radiol. 2013 Sep;43(9):1159-65. doi: 10.1007/s00247-013-2645-x. Epub 2013 Apr 6.

PMID:
23563594
2.
3.

Deferoxamine-induced bone dysplasia in the distal femur and patella of pediatric patients and young adults: MR imaging appearance.

Chan Y, Li C, Chu WC, Pang L, Cheng JC, Chik KW.

AJR Am J Roentgenol. 2000 Dec;175(6):1561-6.

PMID:
11090375
4.

MR imaging of deferoxamine-induced bone dysplasia in an 8-year-old female with thalassemia major.

Miller TT, Caldwell G, Kaye JJ, Arkin S, Burke S, Brill PW.

Pediatr Radiol. 1993;23(7):523-4.

PMID:
8309753
5.
6.

Deferoxamine-induced bone dysplasia in patients with thalassemia major.

Brill PW, Winchester P, Giardina PJ, Cunningham-Rundles S.

AJR Am J Roentgenol. 1991 Mar;156(3):561-5.

PMID:
1899759
7.

Patterns of bone diseases in transfusion-dependent homozygous thalassaemia major: predominance of osteoporosis and desferrioxamine-induced bone dysplasia.

Chan YL, Pang LM, Chik KW, Cheng JC, Li CK.

Pediatr Radiol. 2002 Jul;32(7):492-7. Epub 2002 Apr 10.

PMID:
12107582
8.

Radiographic and MRI features of deferiprone-related arthropathy of the knees in patients with beta-thalassemia.

Kellenberger CJ, Schmugge M, Saurenmann T, Di Gennaro L, Eber SW, Willi UV, Babyn PS.

AJR Am J Roentgenol. 2004 Oct;183(4):989-94.

PMID:
15385291
9.

A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance.

Tanner MA, Galanello R, Dessi C, Smith GC, Westwood MA, Agus A, Roughton M, Assomull R, Nair SV, Walker JM, Pennell DJ.

Circulation. 2007 Apr 10;115(14):1876-84. Epub 2007 Mar 19.

10.

Case report 744. Deferoxamine-induced skeletal dysplasia.

Borenstein ZC, Hyman CB, Rimoin DL, Chapman CL, Lachman R.

Skeletal Radiol. 1992;21(8):534-7. No abstract available.

PMID:
1465648
11.

Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction.

Tanner MA, Galanello R, Dessi C, Smith GC, Westwood MA, Agus A, Pibiri M, Nair SV, Walker JM, Pennell DJ.

J Cardiovasc Magn Reson. 2008 Feb 25;10:12. doi: 10.1186/1532-429X-10-12.

12.

Cardiac events and cardiac T2* in Egyptian children and young adults with beta-thalassemia major taking deferoxamine.

Elalfy MS, Abdin IA, El Safy UR, Ibrahim AS, Ebeid FS, Salem DS.

Hematol Oncol Stem Cell Ther. 2010;3(4):174-8.

13.

Long-term follow-up of skeletal dysplasia in thalassaemia major.

Naselli A, Vignolo M, Di Battista E, Garzia P, Forni GL, Traverso T, Aicardi G.

J Pediatr Endocrinol Metab. 1998;11 Suppl 3:817-25.

PMID:
10091152
14.

Renal dysfunction in patients with beta-thalassemia major receiving iron chelation therapy either with deferoxamine and deferiprone or with deferasirox.

Economou M, Printza N, Teli A, Tzimouli V, Tsatra I, Papachristou F, Athanassiou-Metaxa M.

Acta Haematol. 2010;123(3):148-52. doi: 10.1159/000287238. Epub 2010 Feb 24.

PMID:
20185899
15.

Four-year evaluation of myocardial and liver iron assessed prospectively with serial MRI scans in young patients with beta-thalassaemia major: comparison between different chelation regimens.

Christoforidis A, Haritandi A, Tsatra I, Tsitourides I, Karyda S, Athanassiou-Metaxa M.

Eur J Haematol. 2007 Jan;78(1):52-7. Epub 2006 Sep 28.

PMID:
17042760
16.

Improving survival with deferiprone treatment in patients with thalassemia major: a prospective multicenter randomised clinical trial under the auspices of the Italian Society for Thalassemia and Hemoglobinopathies.

Maggio A, Vitrano A, Capra M, Cuccia L, Gagliardotto F, Filosa A, Magnano C, Rizzo M, Caruso V, Gerardi C, Argento C, Campisi S, Cantella F, Commendatore F, D'Ascola DG, Fidone C, Ciancio A, Galati MC, Giuffrida G, Cingari R, Giugno G, Lombardo T, Prossomariti L, Malizia R, Meo A, Roccamo G, Romeo MA, Violi P, Cianciulli P, Rigano P.

Blood Cells Mol Dis. 2009 May-Jun;42(3):247-51. doi: 10.1016/j.bcmd.2009.01.002. Epub 2009 Feb 23.

PMID:
19233692
17.
19.

Growth hormone secretion and bone histomorphometric study in thalassaemic patients with acquired skeletal dysplasia secondary to desferrioxamine.

De Sanctis V, Stea S, Savarino L, Scialpi V, Traina GC, Chiarelli GM, Sprocati M, Govoni R, Pezzoli D, Gamberini R, Rigolin F.

J Pediatr Endocrinol Metab. 1998;11 Suppl 3:827-33.

PMID:
10091153
20.

Audiologic and vestibular assessment in patients with β-thalassemia major receiving long-term transfusion therapy.

Chao YH, Wu KH, Lin CY, Tsai MH, Peng CT, Wu HP, Lin CD.

Pediatr Blood Cancer. 2013 Dec;60(12):1963-6. doi: 10.1002/pbc.24699. Epub 2013 Aug 19.

PMID:
23956204
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk